181 related articles for article (PubMed ID: 22517848)
1. Cancer. Heterogeneity and tumor history.
Shibata D
Science; 2012 Apr; 336(6079):304-5. PubMed ID: 22517848
[No Abstract] [Full Text] [Related]
2. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.
Saeed K; Ojamies P; Pellinen T; Eldfors S; Turkki R; Lundin J; Järvinen P; Nisen H; Taari K; Af Hällström TM; Rannikko A; Mirtti T; Kallioniemi O; Östling P
Int J Cancer; 2019 Mar; 144(6):1356-1366. PubMed ID: 30125350
[TBL] [Abstract][Full Text] [Related]
3. SnapShot: Renal Cell Carcinoma.
Turajlic S; Larkin J; Swanton C
Cell; 2015 Dec; 163(6):1556-1556.e1. PubMed ID: 26638079
[TBL] [Abstract][Full Text] [Related]
4. Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation.
Jones TD; Eble JN; Wang M; Maclennan GT; Jain S; Cheng L
Cancer; 2005 Sep; 104(6):1195-203. PubMed ID: 16047350
[TBL] [Abstract][Full Text] [Related]
5. Words of wisdom. Re: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Tannock IF
Eur Urol; 2014 Apr; 65(4):846-7. PubMed ID: 24559903
[No Abstract] [Full Text] [Related]
6. Constraints in cancer evolution.
Venkatesan S; Birkbak NJ; Swanton C
Biochem Soc Trans; 2017 Feb; 45(1):1-13. PubMed ID: 28202655
[TBL] [Abstract][Full Text] [Related]
7. Third-Line Treatment Options for Kidney Cancer.
Posadas EM; Limvorasak S; Figlin RA
Oncology (Williston Park); 2016 Sep; 30(9):813-5. PubMed ID: 27633411
[No Abstract] [Full Text] [Related]
8. [Therapeutic indication of interferons for renal cell carcinoma].
Harano M; Naito S
Nihon Rinsho; 2006 Feb; 64 Suppl 2():647-51. PubMed ID: 16523970
[No Abstract] [Full Text] [Related]
9. Tumour heterogeneity and cancer cell plasticity.
Meacham CE; Morrison SJ
Nature; 2013 Sep; 501(7467):328-37. PubMed ID: 24048065
[TBL] [Abstract][Full Text] [Related]
10. Lack of KRAS and BRAF mutation in renal cell carcinoma.
Gattenlöhner S; Etschmann B; Riedmiller H; Müller-Hermelink HK
Eur Urol; 2009 Jun; 55(6):1490-1. PubMed ID: 19282104
[No Abstract] [Full Text] [Related]
11. Heterogeneity of DNA index in renal-cell carcinoma.
Devonec M; Bringuier PP; Hijazi A; Dutrieux-Berger N; Revillard JP; Perrin P
Prog Clin Biol Res; 1990; 348():35-48. PubMed ID: 2385607
[No Abstract] [Full Text] [Related]
12. Molecular pathology of renal cell carcinoma.
Störkel S
Urologe A; 2004 Sep; 43 Suppl 3():S118-9. PubMed ID: 15164177
[No Abstract] [Full Text] [Related]
13. Kidney cancer: not a single disease.
Pospihalj B; Zamparese R; Mazzucchelli R; Morichetti D
Anal Quant Cytol Histol; 2007 Dec; 29(6):377-9. PubMed ID: 18228653
[No Abstract] [Full Text] [Related]
14. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
Wu M; Si S; Li Y; Schoen S; Xiao GQ; Li X; Teh BT; Wu G; Chen J
Oncotarget; 2015 Oct; 6(32):32761-73. PubMed ID: 26418749
[TBL] [Abstract][Full Text] [Related]
15. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity.
Calandrini C; Schutgens F; Oka R; Margaritis T; Candelli T; Mathijsen L; Ammerlaan C; van Ineveld RL; Derakhshan S; de Haan S; Dolman E; Lijnzaad P; Custers L; Begthel H; Kerstens HHD; Visser LL; Rookmaaker M; Verhaar M; Tytgat GAM; Kemmeren P; de Krijger RR; Al-Saadi R; Pritchard-Jones K; Kool M; Rios AC; van den Heuvel-Eibrink MM; Molenaar JJ; van Boxtel R; Holstege FCP; Clevers H; Drost J
Nat Commun; 2020 Mar; 11(1):1310. PubMed ID: 32161258
[TBL] [Abstract][Full Text] [Related]
16. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.
Stein MN; Hirshfield KM; Zhong H; Singer EA; Ali SM; Ganesan S
Eur Urol; 2015 Feb; 67(2):353-4. PubMed ID: 25457019
[No Abstract] [Full Text] [Related]
17. Clonal architectures predict clinical outcome in clear cell renal cell carcinoma.
Huang Y; Wang J; Jia P; Li X; Pei G; Wang C; Fang X; Zhao Z; Cai Z; Yi X; Wu S; Zhang B
Nat Commun; 2019 Mar; 10(1):1245. PubMed ID: 30886153
[TBL] [Abstract][Full Text] [Related]
18. Rapid Response to Nivolumab in a Patient With Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma.
Rouvinov K; Osyntsov L; Shaco-Levy R; Baram N; Ariad S; Mermershtain W
Clin Genitourin Cancer; 2017 Dec; 15(6):e1127-e1130. PubMed ID: 28673798
[No Abstract] [Full Text] [Related]
19. Early and late genetic changes in clear cell renal carcinoma.
Moch H
Urologe A; 2004 Sep; 43 Suppl 3():S121. PubMed ID: 15164178
[No Abstract] [Full Text] [Related]
20. Computing tumor trees from single cells.
Davis A; Navin NE
Genome Biol; 2016 May; 17(1):113. PubMed ID: 27230879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
